

CITATION REPORT

List of articles citing

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

DOI: 10.1016/j.atherosclerosis.2011.06.028
Atherosclerosis, 2011, 217, 3-46.

Source: <https://exaly.com/paper-pdf/50447471/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
503	The evolution of domain arrangements in proteins and interaction networks. 2005 , 62, 435-45		100
502	Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. 2011 , 10, 212		4
501	Adherence to lipid-lowering treatment: the patient perspective. 2012 , 6, 805-14		31
500	Current world literature. 2012 , 27, 441-54		
499	Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. 2012 , 27, 405-11		15
498	Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. 2012 , 166, 487-92		27
497	Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. 2012 , 11, 753-66		47
496	Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?. 2012 , 7, 549-559		4
495	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. 2012 , 8, 813-7		2
494	Implementation, target population, compliance and barriers to risk guided therapy. 2012 , 19, 37-41		6
493	Actualizaci3n en el manejo del colesterol hdl bajo. 2012 , 23, 689-692		
492	Familial hypercholesterolaemia and dyslipidaemias: new international guidelines for clinical practice. 2012 , 12, 130-134		
491	Established and emerging approaches for the management of dyslipidaemia. 2012 , 2012, 482423		0
490	Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. 2012 , 50, 1169-81		10
489	Safety of long-term simvastatin discontinuation. 2012 , 379, 1704; author reply 1704		
488	Insuficiencia renal cr3nica y estatinas. 2012 , 24, 297-298		
487	News from the literature: focus on joint ESC/EAS dyslipidemia guidelines. <i>Atherosclerosis</i> , 2012 , 220, 42-4	3.1	1

486	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. <i>Atherosclerosis</i> , 2012 , 224, 150-3	3.1	29
485	[The long haul to achieve the objectives in the treatment of dyslipidaemias]. 2012 , 212, 488-90		0
484	Magnitude and Management of Hypercholesterolemia in the Adult Population of Spain, 2008-2010: The ENRICA Study. 2012 , 65, 551-558		2
483	Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. <i>Atherosclerosis</i> , 2012 , 225, 388-96	3.1	26
482	LDL-cholesterol target values and actual values in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic monotherapy: the lipid results of the French ESCALADE survey. 2012 , 73, 503-9		
481	Progress and prospective of plant sterol and plant stanol research: report of the Maastricht meeting. <i>Atherosclerosis</i> , 2012 , 225, 521-33	3.1	50
480	Concepto y componentes del riesgo residual. 2012 , 24, 8-13		
479	Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. 2012 , 46, e5		6
478	Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: The ENRICA Study. 2012 , 65, 551-8		92
477	Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. 2012 , 345, e5244		83
476	Bêfice cardiovasculaire des statines dans le haut risque vasculaire. 2012 , 4, 259-267		
475	Metabolic syndrome and vascular risk estimation in a Mediterranean non-diabetic population without cardiovascular disease. 2012 , 23, 558-63		9
474	Dyslipoproteinämie und körperliche Aktivität. 2012 , 8, 562-567		
473	Treatment targets in the management of dyslipidemias: which targets in whom?. 2012 , 14, 692-700		3
472	Update on guidelines for management of hypercholesterolemia. 2012 , 10, 1239-49		3
471	Approach to cardiovascular disease prevention in patients with chronic kidney disease. 2012 , 14, 391-413		7
470	Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. 2012 , 110, 307-13		32
469	Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. 2012 , 11, 18		9

468	Novel pharmacotherapies of familial hyperlipidemia. 2013 , 139, 301-12		2
467	Family history of coronary heart disease and markers of subclinical cardiovascular disease: where do we stand?. <i>Atherosclerosis</i> , 2013 , 228, 285-94	3.1	30
466	Type 2 diabetes and cardiovascular disease in women. 2013 , 56, 1-9		69
465	Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. 2013 , 15, 397		25
464	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. 2013 , 14, 237-42		21
463	Characterization of lipid profile in primary health care users in Portugal. 2013 , 32, 987-996		6
462	[Characterization of lipid profile in primary health care users in Portugal]. 2013 , 32, 987-96		10
461	Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. <i>Atherosclerosis</i> , 2013 , 229, 161-8	3.1	65
460	High triglyceride-to-HDL cholesterol ratio associated with albuminuria in type 2 diabetic subjects. 2013 , 27, 243-7		13
459	Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol. 2013 , 167, 403-8		15
458	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. 2013 , 170, S16-20		26
457	Protocolo terapéutico del síndrome metabólico. 2013 , 11, 2434-2437		
456	Caso clínico de dislipidemia mixta. 2013 , 11, 2438.e1-2438.e2		
455	Protocolo diagnóstico de las dislipidemias. 2013 , 11, 2424-2428		
454	Protocolo terapéutico de las dislipidemias. 2013 , 11, 2429-2433		
453	Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. 2013 , 112, 1885-95		34
452	Cardiovascular risk in rheumatoid arthritis: how to lower the risk?. <i>Atherosclerosis</i> , 2013 , 231, 163-72	3.1	48
451	Pharmacogenetics and cardiovascular disease--implications for personalized medicine. 2013 , 65, 987-1009		93

450	Argan oil prevents prothrombotic complications by lowering lipid levels and platelet aggregation, enhancing oxidative status in dyslipidemic patients from the area of Rabat (Morocco). 2013 , 12, 107		14
449	What have we learnt about high-density lipoprotein cholesterol measurements during 32 years? Experiences in Finland 1980-2012. 2013 , 415, 118-23		12
448	The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment. 2013 , 65, 223-232		4
447	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. 2013 , 29, 1395-9		3
446	[Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention]. 2013 , 25, 92-7		1
445	Long-term use of statins reduces the risk of hospitalization for dementia. <i>Atherosclerosis</i> , 2013 , 230, 171-6	3.1	32
444	How will new medications affect the lipoprotein apheresis situation in Germany?. 2013 , 14, 71-2		6
443	Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. <i>Atherosclerosis</i> , 2013 , 230, 347-53	3.1	101
442	[Atherogenic dyslipidemia: a multidisciplinary consensus panel]. 2013 , 25, 83-91		1
441	Discordance: can we capitalize on it to better personalize atherosclerosis treatment?. <i>Atherosclerosis</i> , 2013 , 229, 504-6	3.1	6
440	Relationship among low cholesterol levels, depressive symptoms, aggression, hostility, and cynicism. 2013 , 7, 208-16		25
439	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. 2013 , 7, 292-303		13
438	Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. <i>Atherosclerosis</i> , 2013 , 226, 296-8	3.1	5
437	New EAS Consensus Statement on FH: improving the care of FH patients. <i>Atherosclerosis</i> , 2013 , 231, 69-71		9
436	The necessity for clinical reasoning in the era of evidence-based medicine. 2013 , 88, 1108-14		53
435	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. 2013 , 7, 399-407		18
434	[Expert consensus on the detection and clinical management of familial hypercholesterolemia]. 2013 , 25, 182-93		12
433	Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. 2013 , 14 Suppl 1, 1-11		22

432	The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. 2013 , 14, 691-7		19
431	Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?. <i>Atherosclerosis</i> , 2013 , 228, 329-31	3.1	1
430	HDL function and cardiovascular risk: debate continues. <i>Atherosclerosis</i> , 2013 , 229, 38-41	3.1	2
429	Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes. 2013 , 11, 327-42		21
428	La prévention des facteurs de risque cardiovasculaire chez la personne âgée. 2013 , 5, 223-224		
427	A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. 2013 , 10, 277-86		16
426	Lipoprotein apheresis: an update. 2013 , 8, 693-705		24
425	Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic Study of Atherosclerosis. 2013 , 33, 652-8		26
424	Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. 2013 , 2, e000037		12
423	Schwere, asymptomatische Hypercholesterinämie im jungen Lebensalter. 2013 , 13, 39-44		
422	Is mipomersen ready for clinical implementation? A transatlantic dilemma. 2013 , 24, 301-6		18
421	Is the atherosclerotic phenotype of preeclamptic placentas due to altered lipoprotein concentrations and placental lipoprotein receptors? Role of a small-for-gestational-age phenotype. 2013 , 54, 2658-64		19
420	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. 2013 , 8, 13-41		21
419	Predictors of coronary lesions complexity in patients with stable coronary artery disease. 2013 , 64, 304-9		16
418	Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. 2013 , 28, 554-60		38
417	Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. 2013 , 51, 1217-26		37
416	Inflammation Markers in Patients with Cardiovascular Disease and Metabolic Syndrome. 2013 , 32, 214-219		11
415	Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. 2013 , 6, 360-6		11

414	Intersubject variability of blood analysis reference values: assessment of age and locality influence by means of a linear discriminant analysis model. 2013 , 27, 237-44	1
413	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. 2013 , 67, 391-3	
412	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. 2013 , 274, 252-62	57
411	Beyond statins: what to expect from add-on lipid regulating therapy?. 2013 , 34, 2660-5	18
410	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. 2013 , 22, 1411-23	18
409	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. 2013 , 8, 243-256	2
408	Affections métaboliques et psychiatrie. 2013 , 10, 1-17	
407	Classification of LDL phenotypes by 4 methods of determining lipoprotein particle size. 2013 , 61, 942-9	19
406	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. 2013 , 9, 273-82	5
405	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. 2013 , 9, 719-27	24
404	Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. 2014 , 9, e84350	37
403	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. 2014 , 10, 237-46	9
402	Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. 2014 , 10, 225-35	7
401	DIAGNOSIS AND TREATMENT OF PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA IN REAL OUTPATIENT PRACTICE (ACCORDING TO THE RECVASA REGISTRY). 2014 , 10, 612-616	12
400	Dysfunctional HDL: the journey from savior to slayer. 2014 , 9, 49-59	10
399	Effectiveness of treat-to-target strategy for LDL-cholesterol control in type 2 diabetes: post-hoc analysis of data from the MIND.IT study. 2014 , 21, 456-63	2
398	Dyslipidemias and chronic kidney disease: a focus on pathogenesis and treatment. 2014 , 9, 673-681	3
397	Identifying pseudohypertriglyceridemia in clinical practice. 2014 , 9, 625-641	8

396	A randomized study on lipids response to different exercise programs in overweight older men. 2014 , 35, 1106-11	3
395	Clinician's guide to the updated ABCs of cardiovascular disease prevention. 2014 , 3, e001098	17
394	Reaching low density lipoprotein cholesterol targets. 2014 , 30, 1967-9	10
393	[Familial combined hyperlipidemia: consensus document]. 2014 , 46, 440-6	8
392	Predictive factors of achieving therapeutic goals of hypertriglyceridemia. 2014 , 30, 19-26	8
391	Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. 2014 , 90, 722-9	9
390	Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. 2014 , 64, 2525-40	149
389	National Lipid Association Annual Summary of Clinical Lipidology 2015. 2014 , 8, S1-36	56
388	Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database. 2014 , 48, 847-855	2
387	Efficacy and safety of ezetimibe plus atorvastatin therapy. 2014 , 9, 441-470	5
386	Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: an alternative equation for accurate estimation and improved cardiovascular risk classification. 2014 , 11, 431-9	6
385	SURF - SURvey of Risk Factor management: first report of an international audit. 2014 , 21, 813-22	15
384	Postprandial hypertriglyceridemia as a coronary risk factor. 2014 , 431, 131-42	138
383	Use of ezetimibe results in more patients reaching lipid targets without side effects. 2014 , 56, e128-e132	3
382	Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. 2014 , 8, 441-7	15
381	Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods. <i>Atherosclerosis</i> , 2014 , 234, 142-5	3.1 8
380	The results of Look AHEAD do not row against the implementation of lifestyle changes in patients with type 2 diabetes. 2014 , 24, 4-9	5
379	Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA ₂) and lipoprotein(a) (Lp(a)). 2014 , 28, 281-94	19

378	LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy. 2014 , 36, 792-9		3
377	Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. <i>Atherosclerosis</i> , 2014 , 234, 42-6	3-1	33
376	[New approaches for the treatment of dyslipidemia]. 2014 , 142, 306-9		
375	Impact of gender and age on risk factor distribution and health perception: evaluation in a prospective population with heart disease. 2014 , 22, 219-226		
374	The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view. <i>Atherosclerosis</i> , 2014 , 234, 473-5	3-1	19
373	Lipid, blood pressure and kidney update 2013. 2014 , 46, 947-61		47
372	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. 2014 , 125-139		1
371	Lipoprotein(a): Structure, Metabolism, and Pathophysiology. 2014 , 141-155		
370	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. 2014 , 8, 29-60		246
369	2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. 2014 , 63, 2674-8		47
368	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014 , 233, 508-509	3-1	2
367	Serum lipid concentrations among persons with spinal cord injury - a systematic review and meta-analysis of the literature. <i>Atherosclerosis</i> , 2014 , 232, 305-12	3-1	41
366	Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. 2014 , 23, 1817-28		58
365	[Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. 2014 , 35, 723-9		4
364	Emerging drugs for hyperlipidaemia: an update. 2014 , 19, 471-88		5
363	Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. 2014 , 55, 2408-15		56
362	Variación biológica de lípidos y lipoproteínas séricas en individuos sanos y pacientes con enfermedad renal crónica terminal. 2014 , 7, 88-95		
361	The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. 2014 , 73, 1301-8		94

360	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. 2014 , 15, 33-45		25
359	Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). 2014 , 50, 44-53		4
358	[Familial combined hyperlipidemia: consensus document]. 2014 , 40, 374-80		5
357	Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. 2014 , 15, 26-32		18
356	Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia. 2014 , 55, 947-55		16
355	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. 2014 , 8, 373-80		2
354	[Atherosclerosis in systemic lupus erythematosus]. 2014 , 43, 1034-47		9
353	Combination therapy in dyslipidemia: where are we now?. <i>Atherosclerosis</i> , 2014 , 237, 319-35	3.1	34
352	Statins for all?. 2014 , 114, 1443-6		7
351	Personalized approach to primary and secondary prevention of ischemic stroke. 2014 , 5, 9		7
350	National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. 2014 , 8, 473-88		323
349	Berberine and monacolin effects on the cardiovascular risk profile of women with oestrogen-induced hypercholesterolemia. 2014 , 21, 221-6		11
348	High-density lipoprotein subfractions: current views and clinical practice applications. 2014 , 25, 329-36		33
347	Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. 2014 , 10, 183-99		34
346	Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults. 2014 , 8, 501-9		8
345	Statins and the risk of diabetes: evidence from a large population-based cohort study. 2014 , 37, 2225-32		72
344	New strategies for the management of patients with homozygous familial hypercholesterolaemia. 2014 , 15, 17-8		
343	Seasonality of cardiovascular risk factors: an analysis including over 230 000 participants in 15 countries. 2014 , 100, 1517-23		88

342	Use of expert consensus to improve atherogenic dyslipidemia management. 2014 , 67, 36-44		2
341	[Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia]. 2014 , 26, 176-83		2
340	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. <i>Atherosclerosis</i> , 2014 , 233, 83-90	3.1	39
339	Ultrasonography managed by internists: the stethoscope of 21st century?. 2014 , 214, 155-60		12
338	Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica. 2014 , 67, 36-44		22
337	Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys). 2014 , 56, e98-e104		6
336	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. 2014 , 8, 107-16		26
335	Ultrasonography managed by internists: The stethoscope of 21st century?. 2014 , 214, 155-160		0
334	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. 2014 , 2, 455-63		68
333	Statins decrease thrombin generation in patients with hypercholesterolemia. 2014 , 25, 449-51		12
332	Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease. <i>Atherosclerosis</i> , 2014 , 235, 281-8	3.1	26
331	Positive effects of football on fitness, lipid profile, and insulin resistance in Brazilian patients with type 2 diabetes. 2014 , 24 Suppl 1, 57-65		58
330	Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease. 2014 , 61, 343-51		5
329	[Trans-intestinal cholesterol excretion (TICE): a new route for cholesterol excretion]. 2014 , 30, 896-901		5
328	Pharmacological lipid lowering for prevention of cardiovascular disease in older adults. 2014 , 11, 49-58		1
327	Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". 2015 , 34, 435-8		
326	Comentário a «Associação entre a hipercolesterolemia familiar e a prevalência de diabetes mellitus». 2015 , 34, 435-438		
325	The Notch pathway: a new therapeutic target in atherosclerosis?. 2015 , 17, A74-A76		9

324	Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study. 2015 , 14, 108		16
323	Communicating risk with relatives in a familial hypercholesterolemia cascade screening program: a summary of the evidence. 2015 , 30, E1-E12		9
322	Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. 2015 , 26, 200-9		44
321	Can we treat to target in osteoporosis?. 2015 , 10, 1-4		3
320	Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials. 2015 , 9, 1859-64		1
319	[Consensus on management of dyslipidemia in pediatrics]. 2015 , 113, 177-86		1
318	Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. 2015 , 22, 272-83		18
317	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. 2015 , 14, 45		11
316	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. 2015 , 39, 353-62		168
315	Medical management of chronic stable angina. 2015 , 38, 131-6		9
314	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. 2015 , 10, e0122414		9
313	Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. 2015 , 10, e0123367		25
312	Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity. 2015 , 39, 23-30		7
311	Novel methodologies for biomarker discovery in atherosclerosis. 2015 , 36, 2635-42		133
310	Lipid-modifying therapy in the elderly. 2015 , 11, 251-63		11
309	Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice. 2015 , 22, 199-201		14
308	To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. <i>Atherosclerosis</i> , 2015 , 241, 450-4	3.1	15
307	Statin use and non-alcoholic steatohepatitis in at risk individuals. 2015 , 63, 705-12		227

306	Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. 2015 , 157-179		
305	Dyslipidemia and Cardiovascular Risk in Obesity. 2015 , 121-130		1
304	Treatment of primary hypertriglyceridemia states--General approach and the role of extracorporeal methods. 2015 , 18, 85-94		12
303	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. 2015 , 16, 1449-61		33
302	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. 2015 , 132, 2167-92		377
301	Cardiovascular disease in HIV patients: from bench to bedside and backwards. 2015 , 2, e000174		56
300	Coronary heart disease prediction: Apolipoprotein B shows its might again--but still in vain?. 2015 , 22, 1317-20		4
299	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. 2015 , 9, S1-122.e1		293
298	The past, present and future of lipid-lowering therapy. 2015 , 10, 481-498		2
297	Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). 2015 , 9, 533-41		26
296	Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice. 2015 , 9, 247-55		16
295	Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. 2015 , 4, e001675		17
294	Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. 2015 , 15, 287-98		6
293	Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. 2015 , 37, 225-241.e8		115
292	Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. <i>Atherosclerosis</i> , 2015 , 239, 439-43	3.1	25
291	Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. 2015 , 42, 645-53		27
290	ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. 2015 , 11, 27-37		45
289	[2013 Guidelines ACC/AHA cardiovascular risk. Incomplete evidence and failed attempt at simplification]. 2015 , 27, 74-9		

288	Early investigational drugs targeting PPAR- α for the treatment of metabolic disease. 2015 , 24, 611-21		34
287	Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2015 , 240, 482-9	3.1	17
286	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. <i>Atherosclerosis</i> , 2015 , 242, 647-56	3.1	45
285	Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. 2015 , 9, 525-32		28
284	Combination Therapy In Dyslipidemia. 2015 ,		3
283	Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. 2015 , 66, 346-53		20
282	The role of apoB measurement in Type 2 diabetic patients. 2015 , 10, 137-144		2
281	Association and interaction of PPAR α and β gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population. 2015 , 19, 379-86		15
280	Statin intolerance: diagnosis and remedies. 2015 , 17, 27		28
279	Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. 2015 , 25, 489-94		48
278	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. 2015 , 26, 82-8		56
277	Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients. 2015 , 65, 403-11		24
276	Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. 2015 , 9, 2129-37		10
275	Quality of buckwheat-enriched wheat bread and its antihyperlipidemic effect in statin treated patients. 2015 , 63, 556-561		25
274	First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. 2015 , 18, 241-50		4
273	Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. 2015 , 18, 163-9		17
272	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. 2015 , 9, 129-69		478
271	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. <i>Atherosclerosis</i> , 2015 , 240, 408-14	3.1	31

270	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. 2015 , 17, 109		20
269	Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. 2015 , 102, 168-75		4
268	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. 2015 , 18, 1270-3		13
267	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015 , 242, 490-5	3.1	28
266	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. 2015 , 35, 968-1031		30
265	Lipid-Lowering Therapy and Apheresis: Indications and Outcomes. 2015 , 143-152		
264	Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy. 2015 , 29, 1262-70		1
263	Simple and rapid determination of unsaturated fatty acids in 1 µl of rat plasma by LC-MS/MS. 2015 , 7, 1081-91		3
262	Perspectives on Cholesterol Guidelines. 2015 , 313-327		
261	Modulation of Cholesterol-Related Gene Expression by Dietary Fiber Fractions from Edible Mushrooms. 2015 , 63, 7371-80		35
260	LDL cholesterol, statins and PCSK 9 inhibitors. 2015 , 67, 419-24		10
259	Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. <i>Atherosclerosis</i> , 2015 , 242, 553-9	3.1	29
258	[Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion]. 2015 , 36, 372-80		7
257	Meal patterns in healthy adults: Inverse association of eating frequency with subclinical atherosclerosis indexes. 2015 , 34, 302-8		10
256	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. 2015 , 9, 629-50		57
255	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. 2015 , 36, 560-5		283
254	Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. 2015 , 67, 169-79		36
253	Clinical Inertia in the Management of Hypercholesterolemia: What Clinicians Need to do. 2016 , 23, 552-3		3

252	Coronary artery disease (CAD) in chronic kidney disease patients. 2016 , 28, 44-52	1
251	HIV Infection and Myocardial Infarction. 2016 , 14, 456-465	4
250	Disorders of Lipid Metabolism. 2016 , 1660-1700	4
249	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. 2016 , 12, 171-83	123
248	Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?. 2016 , 27, 359-66	10
247	Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. 2016 , 23, 145-9	9
246	Deprescribing: An Application to Medication Management in Older Adults. 2016 , 36, 774-80	16
245	Nutritional management of hyperapoB. 2016 , 29, 202-233	16
244	Genetic identification of familial hypercholesterolemia within a single U.S. health care system. 2016 , 354,	229
243	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. 2017 , 3, 92-97	22
242	Trastornos del metabolismo lipídico. 2016 , 12, 1059-1071	
241	Protocolo diagnóstico de las dislipidemias. 2016 , 12, 1107-1110	
240	The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease. 2016 , 11, 3-6	4
239	Comparison of statin eligibility according to the Adult Treatment Panel III, ACC/AHA blood cholesterol guideline, and presence of carotid plaque by ultrasound in Mexican mestizo patients with rheumatoid arthritis. 2016 , 35, 2823-2827	5
238	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84	22
237	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. 2016 , 117, 1444-8	61
236	The metabolic vascular syndrome - guide to an individualized treatment. 2016 , 17, 5-17	25
235	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. 2016 , 54, 588-601	48

234	Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. 2016 , 10, 116-23		1
233	Statin combination therapy and cardiovascular risk reduction. 2016 , 12, 289-315		9
232	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. 2016 , 65, 1664-1678		45
231	Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy. 2016 , 10, 1470-1480.e3		1
230	Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study. 2017 , 19, 826-835		9
229	Berberine and Its Role in Chronic Disease. 2016 , 928, 27-45		106
228	Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. 2016 , 8, 180-191		17
227	The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. 2016 , 15, 118		91
226	Consensus statement on the management of dyslipidaemias in adults. 2016 , 42, 398-408		14
225	Left Ventricular Mechanics in Functional Ischemic Mitral Regurgitation in Acute Inferoposterior Myocardial Infarction. 2016 , 33, 1131-42		5
224	Managing the lipid profile of coronary heart disease patients. 2016 , 14, 1263-1271		5
223	Safety of atorvastatin in Asian patients within clinical trials. 2016 , 34, 431-440		14
222	Non-High-Density Lipoprotein Cholesterol Levels on the Risk of Asymptomatic Intracranial Arterial Stenosis: A Result from the APAC Study. 2016 , 6, 37410		8
221	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016 , 252, 1-8	3.1	20
220	Prognostic value of an abnormal response to acetylcholine in patients with angina and non-obstructive coronary artery disease: Long-term follow-up of the Heart Quest cohort. 2016 , 221, 539-45		7
219	A competing-risk-based score for predicting twenty-year risk of incident diabetes: the Beijing Longitudinal Study of Ageing study. 2016 , 6, 37248		6
218	Olive oil and postprandial hyperlipidemia: implications for atherosclerosis and metabolic syndrome. 2016 , 7, 4734-4744		19
217	Tobacco smoking and cytokine levels in human epicardial adipose tissue: Impact of smoking cessation. <i>Atherosclerosis</i> , 2016 , 255, 37-42	3.1	13

216	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. 2016 , 9, 348-54		3
215	Drug treatment and adherence of subjects . <i>Atherosclerosis</i> , 2016 , 254, 172-178	3.1	6
214	Prediction of the 20-year incidence of diabetes in older Chinese: Application of the competing risk method in a longitudinal study. 2016 , 95, e5057		6
213	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. 2016 , 17, 110		11
212	Lipidtherapie bei Diabetes mellitus. 2016 , 16, 42-46		
211	Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. 2016 , 39, 1408-15		94
210	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. 2016 , 128 Suppl 2, S216-28		4
209	Association of fish consumption and dietary intake of marine n-3 PUFA with myocardial infarction in a prospective Danish cohort study. 2016 , 116, 167-77		14
208	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. 2016 , 10, 273-82		27
207	[In Process Citation]. 2016 , 28 Suppl 1, 1-49		0
206	Quality of deli-style turkey enriched with plant sterols. 2016 , 22, 743-751		7
205	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. 2016 , 14, 4		51
204	The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. 2016 , 49, 47-56		1
203	Influence of Ultraviolet Radiation on the Association between 25-Hydroxy Vitamin D Levels and Cardiovascular Risk Factors in Obesity. 2016 , 171, 83-9.e1		18
202	Evolocumab: A Review in Hyperlipidemia. 2016 , 16, 67-78		6
201	[PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?]. 2016 , 41, 217-23		1
200	Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors. 2016 , 16, 234		40
199	National Lipid Association Annual Summary of Clinical Lipidology 2016. 2016 , 10, S1-43		74

198	Update on the molecular biology of dyslipidemias. 2016 , 454, 143-85	80
197	Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. <i>Atherosclerosis</i> , 2016 , 244, 86-92 ³⁻¹	41
196	Blood lipid levels associate with childhood asthma, airway obstruction, bronchial hyperresponsiveness, and aeroallergen sensitization. 2016 , 137, 68-74.e4	36
195	PCSK9 and diabetes: is there a link?. 2017 , 22, 883-895	25
194	Statins usage and target achievement of LDL-C level in Chinese patients with coronary artery disease impacted by 2013 ACC/AHA cholesterol guideline. 2017 , 14, 33-37	5
193	Consensus statement on the management of dyslipidaemias in adults. 2017 , 78, 43-53	3
192	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. 2017 , 70, 72-77	3
191	Comentarios a la guâ ESC/EAS 2016 sobre el tratamiento de las dislipemias. 2017 , 70, 72-77	8
190	Ezetimibe: an update on its clinical usefulness in specific patient groups. 2017 , 8, 4-11	26
189	Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. 2017 , 11, 674-681	22
188	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. 2017 , 33, 869-876	5
187	Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management. 2017 , 36, 1387-1393	4
186	Resistant Atherosclerosis: The Need for Monitoring of Plaque Burden. 2017 , 48, 1624-1629	28
185	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. 2017 , 28, 374-379	9
184	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. 2017 , 24, 313-329	7
183	Triglycerides Revisited to the Serial. 2017 , 80, 1-44	3
182	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. 2017 , 122, 105-117	16
181	Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. 2017 , 24, 1297-1307	20

180	Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the AIFA-I-GrADE observational project. 2017 , 26, 775-784		11
179	Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. 2017 , 11, 485-494		8
178	[Analysis of Secondary Data to Determine the Prevalence of Cardiovascular High Risk Patients with Hypercholesterolemia and Refractory Course of Treatment]. 2017 , 142, e34-e41		1
177	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. 2017 , 51, 529-542		2
176	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. 2017 , 34, 300-323		29
175	Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. 2017 , 7, e017587		4
174	Adiposity measures and arterial stiffness in primary care: the MARK prospective observational study. 2017 , 7, e016422		12
173	Streptococcus thermophilus fermented milk reduces serum MDA-LDL and blood pressure in healthy and mildly hypercholesterolaemic adults. 2017 , 8, 171-178		15
172	A simple method for extraction and purification of pedunculoside from the dried barks of Ilex rotunda and its inhibitory effect on pancreatic lipase in vitro. 2017 , 52, 2878-2887		3
171	Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. <i>Atherosclerosis</i> , 2017 , 266, 158-166	3.1	64
170	Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina. 2017 , 11, 979-990		15
169	Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levels. 2017 , 18 Suppl 1, e91-e93		1
168	Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. 2017 , 30, 187-192		10
167	Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. 2017 , 6, 81-85		5
166	Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia. <i>Atherosclerosis</i> , 2017 , 265, 22-28	3.1	11
165	Translation and adaptation of the French version of the Heart Disease Fact Questionnaire - Rheumatoid Arthritis (HDFQ-RA 1&2). 2017 , 84, 693-698		2
164	Obstructive sleep apnea is associated with visit-to-visit variability in low-density lipoprotein-cholesterol in patients with coronary artery disease. 2017 , 21, 271-278		6
163	Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. 2017 , 37, 49-55		27

162	Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein and lipoprotein particle levels compared with extra-virgin olive oil. 2017 , 71, 33-38	24
161	Serum lipid profile and fatty acid composition of erythrocyte phospholipids in children and adolescents with primary hyperlipidemia. 2017 , 68, 339-348	5
160	The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review. 2017 , 72, 370-379	7
159	A Mini-Review on the Effect of Docosahexaenoic Acid (DHA) on Cerulein-Induced and Hypertriglyceridemic Acute Pancreatitis. 2017 , 18,	11
158	The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke. 2017 , 13, 1049-1056	15
157	Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans. 2017 , 58, 975-980	1
156	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. 2017 , 13, 29-41	14
155	Lp(a) in Childhood. 2017 , 11, 1	0
154	Added sugars: Definitions, classifications, metabolism and health implications. 2017 , 30, 663-677	5
153	Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction. 2017 , 47, 31-35	5
152	Advances in Hypercholesterolemia. 2017 , 663-693	1
151	Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. 2017 , 7, e016604	12
150	Evaluation of a new equation for LDL-c estimation and prediction of death by cardiovascular related events in a German population-based study cohort. 2018 , 78, 187-196	4
149	Diabetes and lipid metabolism. 2018 , 17, 61-67	81
148	Low density lipoprotein interferes with intracellular signaling of monocytes resulting in impaired chemotaxis and enhanced chemokinesis. 2018 , 255, 160-165	3
147	Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. 2018 , 319, 241-254	481
146	Sense of Coherence, Smoking Status, Biochemical Cardiovascular Risk Factors and Body Mass in Blue Collar Workers-Short Report. 2018 , 12, 894-899	5
145	Diet for stroke prevention. 2018 , 3, 44-50	19

144	Association Between Serum LDL-C and ApoB and SYNTAX Score in Patients With Stable Coronary Artery Disease. 2018 , 69, 724-729		8
143	Association between the polymorphisms and serum lipid traits, the risk of coronary artery disease and ischemic stroke in a southern Chinese Han population. 2018 , 15, 27		10
142	Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. 2018 , 25, 621-633		13
141	[LDL-cholesterol and cardiovascular events: the lower the better?]. 2018 , 168, 108-120		4
140	Plasma biomarker levels and non-obstructive coronary artery disease determined by coronary computed tomography angiography. 2018 , 38, 246-253		2
139	The effect of plant sterol-enriched turkey meat on cholesterol bio-accessibility during in vitro digestion and Caco-2 cell uptake. 2018 , 69, 176-182		2
138	Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry. 2018 , 33, 102-112		8
137	Traduction et adaptation de la version française du Heart Disease Fact Questionnaire-Rheumatoid Arthritis (HDFQ-RA 1&2). 2018 , 85, 255-260		
136	Spanish consensus on treat to target for osteoporosis. 2018 , 29, 489-499		12
135	Polymeric bile acid sequestrants: Review of design, in vitro binding activities, and hypocholesterolemic effects. 2018 , 144, 300-317		17
134	Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry. 2018 , 71, 259-267		2
133	The effect of brief versus individually tailored dietary advice on change in diet, lipids and blood pressure in patients with inflammatory joint disease. 2018 , 62,		2
132	Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. 2018 , 19, 485-490		3
131	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. 2018 , 19,		36
130	Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. 2018 , 18, 900		4
129	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2018 , 277, 448-456	3.1	12
128	Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. <i>Atherosclerosis</i> , 2018 , 277, 323-326	3.1	4
127	Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. <i>Atherosclerosis</i> , 2018 , 277, 355-361	3.1	12

126	Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II. 2018 , 130, 707-715		2
125	sP- and sE-selectin in stroke patients with metabolic disorders. 2018 , 52, 599-605		4
124	Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2018 , 277, 204-210	3.1	25
123	The Role of Nutraceuticals in Statin Intolerant Patients. 2018 , 72, 96-118		157
122	Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2018 , 276, 10-14	3.1	20
121	Efficacy of repeated phlebotomies in hypertriglyceridemia and iron overload: A prospective, randomized, controlled trial. 2018 , 12, 1190-1198		4
120	Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease. 2018 , 19, 20-22		3
119	Could Lipid Profile be Used as a Marker of Autonomous Cortisol Secretion in Patients with Adrenal Incidentalomas?. 2018 , 50, 551-555		7
118	Association between circulating full-length angiopoietin-like protein 8 and non-high-density lipoprotein cholesterol levels in Chinese non-diabetic individuals: a cross-sectional study. 2018 , 17, 161		4
117	DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke. 2018 , 17, 30		17
116	Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea. 2018 , 40, 940-951.e7		1
115	Statin treatment reduces matrix degradation capacity of proinflammatory polarized macrophages. 2018 , 110, 49-54		7
114	Recent advances in understanding and managing acute pancreatitis. 2018 , 7,		21
113	Exogenously Added Oxyphytosterols Do Not Affect Macrophage-Mediated Inflammatory Responses. 2018 , 53, 457-462		4
112	Animal models to study bile acid metabolism. 2019 , 1865, 895-911		60
111	Acute and residual effects of aerobic exercise on fructose-induced postprandial lipemia on lean male subjects. 2019 , 58, 2293-2303		3
110	Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. 2019 , 496, 48-54		9
109	Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine. 2019 , 17, 321-330		10

108	Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l'apoB athérogènes dans l'étiologie du diabète de type 2. 2019 , 13, 129-139	2
107	Recent advances in understanding and managing acute pancreatitis. 2019 , 7, 959	14
106	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. 2019 , 15, 821-831	4
105	A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. 2019 , 149, 968-981	36
104	Dietary Patterns in Relation to Components of Dyslipidemia and Fasting Plasma Glucose in Adults with Dyslipidemia and Elevated Fasting Plasma Glucose in Taiwan. 2019 , 11,	9
103	Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. 2019 , 42, 1104-1111	70
102	Statines, myalgies et rhabdomyolyse. 2019 , 86, 344-349	
101	Where periodontitis meets metabolic syndrome-The role of common health-related risk factors. 2019 , 46, 647-656	9
100	Blood Pressure Variability Is Associated with Hearing and Hearing Loss: A Population-Based Study in Males. 2019 , 2019, 9891025	3
99	Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease. 2019 , 17, 2047-2052	1
98	A Validated Method for Cholesterol Determination in Turkey Meat Products Using Relative Response Factors. 2019 , 8,	6
97	The CXCL12 SNPs and their haplotypes are associated with serum lipid traits. 2019 , 9, 19524	1
96	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. 2018 , 24, 3605-3615	4
95	Advanced Lipid Testing. 2019 , 53-60	
94	The Christmas holidays are immediately followed by a period of hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 281, 121-127	3.1 11
93	Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II). 2019 , 74, 399-404	3
92	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. 2019 , 489, 189-195	3
91	Statins, myalgia, and rhabdomyolysis. 2020 , 87, 37-42	16

90	Within subject variability of HDL-cholesterol in HIV-infected patients. 2020 , 132, 162-166	0
89	Age, aging and physiological dysregulation in safety-critical work: a retrospective longitudinal study of helicopter emergency medical services pilots. 2020 , 93, 301-314	1
88	Niacin and hyperlipidemia. 2020 , 263-281	1
87	Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. 2020 , 51, 14-23	3
86	A Novel Risk Score for Type 2 Diabetes Containing Sleep Duration: A 7-Year Prospective Cohort Study among Chinese Participants. 2020 , 2020, 2969105	5
85	Progress of research on dyslipidemia accompanied by nephrotic syndrome. 2020 , 6, 182-187	1
84	Atherosclerosis in Rheumatology: Old and New Insights. 2020 ,	
83	Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. 2020 , 9, 129-144	5
82	Assessment of Beliefs and Attitudes About Statins Posted on Twitter: A Qualitative Study. 2020 , 3, e208953	18
81	Does lipid-lowering medication improve cardiac sympathetic nerve integrity?. 2021 , 28, 1458-1460	0
80	Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia. 2020 , 37, 2169-2183	1
79	Cysteine is a better predictor of coronary artery disease than conventional homocysteine in high-risk subjects under preventive medication. 2020 , 30, 1281-1288	3
78	Effects of a low-fat dietary regimen enriched with soy in children affected with heterozygous familial hypercholesterolemia. 2020 , 36, 150-156	6
77	Dietary habits, lipoprotein metabolism and cardiovascular disease: From individual foods to dietary patterns. 2021 , 61, 1651-1669	10
76	Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels-a Danish registry-based study. 2021 , 7, 181-188	0
75	Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial. 2021 , 35, 2045-2056	8
74	Understanding of Clinical Practice Guidelines for Dyslipidemia. 2021 , 145-151	
73	Bipolar disorders, obesity, and metabolic disturbances: Mechanisms and implications. 2021 , 257-274	

72	Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia. 2021 , 19, 19	3
71	Nutraceuticals and Cardiovascular Disease. 2021 , 67-87	
70	The importance of omega fatty acids for the prevention of cardiovascular disease. 2021 , 24, 90	
69	MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy. 2021 , 14, 83	1
68	Carotid Plaque Is Not Associated With Increased Levels of Interleukin 1, Interleukin 6, and Tumor Necrosis Factor α In Rheumatoid Arthritis. 2021 , 27, e602-e605	0
67	It's time to stop the nonsense of withholding lipid lowering therapy on account of age. <i>Atherosclerosis</i> , 2021 , 323, 56	3.1 2
66	Escalation of lipid-lowering therapy in patients with vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study. 2021 , 11, 8884	1
65	The TELE-DD project on treatment nonadherence in the population with type 2 diabetes and comorbid depression. 2021 , 11, 8889	0
64	Bile acid sequestrants: a review of mechanism and design. 2021 , 73, 855-861	0
63	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. 2021 , 28, 610-618	5
62	Omega-3 Fatty Acids in Erythrocyte Membranes as Predictors of Lower Cardiovascular Risk in Adults without Previous Cardiovascular Events. 2021 , 13,	2
61	Sex-specific differences in blood lipids and lipid ratios in type 2 diabetic foot patients. 2021 ,	0
60	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. 2021 , 2021, 4757170	1
59	Variation of homocysteine levels in rheumatoid arthritis patients: relationship to inflammation, cardiovascular risk factors, and methotrexate. 2021 , 1	1
58	Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy. 2020 , 2176, 69-85	4
57	Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). 2021 , 108, 49-57	16
56	State of the science on cardiometabolic risk after spinal cord injury: recap of the 2013 Asia pre-conference on cardiometabolic disease. 2014 , 20, 105-12	6
55	Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?. 2014 , 9, e102146	33

54	A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. 2014 , 9, e113370	26
53	Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. 2019 , 181, 579-590	4
52	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. 2020 , 15, 1-9	21
51	Diet Therapy in Children with Hypercholesteremia. 2020 , 19, 309-315	2
50	[Clinical Course and Predictors of Ischemic Mitral Regurgitation in Patients with Myocardial Infarctions of Different Localizations]. 2019 , 59, 25-38	1
49	Consensus statement on the assessment of comorbidities in people living with HIV in Romania. 2019 , 9, 198-210	9
48	Is it time to break the fast?-a paradigm shift in clinical lipidology. 2016 , 4, 430	1
47	Socioeconomic characteristics of the population living in Roma settlements and their association with health and health-related behaviour. 2014 , 22 Suppl, S57-64	25
46	Hepameta-- prevalence of hepatitis B/C and metabolic syndrome in population living in separated and segregated Roma settlements: a methodology for a cross-sectional population-based study using community-based approach. 2014 , 22 Suppl, S6-11	24
45	Prevalence and risk factors of subclinical coronary artery disease in patients undergoing carotid endarterectomy: a retrospective cohort study. 2019 , 38, 312-319	4
44	The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis. 2017 , 15, 1-3	7
43	The Treatment of Disorders of Lipid Metabolism. 2016 , 113, 261-8	40
42	Statin-associated myopathy: from genetic predisposition to clinical management. 2014 , 63, S327-34	37
41	Genetic predisposition of human plasma triglyceride concentrations. 2015 , 64, S341-54	7
40	Hypertriglyceridemic waist - a simple clinical tool to detect cardiometabolic risk: comparison with harmonized definition of metabolic syndrome. 2015 , 64, S385-94	7
39	Treatment of hypertriglyceridemia: a review of current options. 2015 , 64, S331-40	18
38	Lipids in liver transplant recipients. 2016 , 22, 3315-24	19
37	Replacement Meal: Effectiveness of a Soluble Powder Rich in Fibers and at Low Glycemic Index in Overweight but Not in Obese Patients. 2017 , 08, 591-597	1

36	Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. 2017 , 37, 366-374	5
35	Absolute risk of cardiovascular disease and lipid management targets. 2013 , 20, 689-97	10
34	Secondary prevention of coronary heart disease in elderly population of Turkey: A subgroup analysis of ELDERTURK study. 2019 , 26, 13-19	8
33	Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). 2013 , 24, 330-8	12
32	Comparison of Secondary Prevention Status between Percutaneous Coronary Intervention and Coronary Artery Bypass Patients. 2017 , 109, 466-474	2
31	Statin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan. 2016 , 32, 23-30	7
30	Assessment of Different Atherogenic Indices as Predictors of Metabolic Syndrome in Spanish Adolescents. 2021 , 10998004211050887	0
29	Lipid Metabolism, Disorders and Therapeutic Drugs - Review. 2021 , 29, 596-604	1
28	Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings. 2013 , 04, 318-324	
27	Management of elevated blood cholesterol in the psychiatric patient: What's new in the guidelines?. 2014 , 4, 100-106	
26	Familial hypercholesterolemia--screening to facilitate early prevention. 2014 , 111, 521-2	
25	Compendium of Inflammatory Diseases. 2016 , 140-149	
24	7th Brazilian Guideline of Arterial Hypertension: Chapter 3 - Clinical and Complementary Assessment. 2016 , 107, 18-24	2
23	New options in the treatment of hypercholesterolaemia. 2016 , 18, 6-8	
22	Counterpoint: Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?. 2018 , 111, 750-752	
21	Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?. 2018 , 111, 747-749	2
20	MULTIMARKER DIAGNOSTIC PANELS FOR ATHEROSCLEROSIS. 2018 , 65-73	4
19	Some causes of poor adherence to long-term statin therapy and their solution. 2018 , 64, 923-927	1

18	Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. 2020 , 35, 367-376	1
17	Effects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with Hypercholesterolemia. 2020 , 35, 298-307	2
16	Low density Lipoprotein cholesterol target: Changing goal posts. 2012 , 16, S233-5	
15	Goal attainments and their discrepancies for low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B) in over 2,000 Chinese patients with known coronary artery disease or type 2 diabetes. 2015 , 5, 98-103	
14	When do paediatric patients with familial hypercholesterolemia need statin therapy?. 2017 , 21, 43-50	
13	Low density Lipoprotein cholesterol target: Changing goal posts. 2012 , 16, 233	0
12	Undertreatment or Overtreatment With Statins: Where Are We?. 2022 , 9, 808712	1
11	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. 2022 , 9,	0
10	Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity.	2
9	Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up. 2022 ,	
8	Efficacy and Safety Differences between Domestic Paclitaxel Drug-Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral-Popliteal Arteries Type IIA. 2022 , 2022, 1-5	0
7	Correlation Between Serum Uric Acid Levels and Coronary Plaque Characteristics on Optical Coherence Tomography. 2022 , 63, 806-813	0
6	Prevalence and Prognostic Implications of Moderate or Severe Mitral Regurgitation in Patients with Bicuspid Aortic Valve. 2022 ,	0
5	Dyslipidemia is associated with worse asthma clinical outcomes: a prospective cohort study. 2022 ,	0
4	Atherosclerosis. 2016 , 1-10	0
3	Real-World Use of Alirocumab: Experience from a Large Healthcare Provider. 2023 , 12, 1084	0
2	LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis. 2023 ,	0
1	Statine im Alter. 2012 , 88, 339-340	0

